259 related articles for article (PubMed ID: 32066439)
1. Impact of polyunsaturated fatty acids on patient-important outcomes in children and adolescents with autism spectrum disorder: a systematic review.
De Crescenzo F; D'Alò GL; Morgano GP; Minozzi S; Mitrova Z; Saulle R; Cruciani F; Fulceri F; Davoli M; Scattoni ML; Nardocci F; Schünemann HJ; Amato L;
Health Qual Life Outcomes; 2020 Feb; 18(1):28. PubMed ID: 32066439
[TBL] [Abstract][Full Text] [Related]
2. Impact of antipsychotics in children and adolescents with autism spectrum disorder: a systematic review and meta-analysis.
D'Alò GL; De Crescenzo F; Amato L; Cruciani F; Davoli M; Fulceri F; Minozzi S; Mitrova Z; Morgano GP; Nardocci F; Saulle R; Schünemann HJ; Scattoni ML;
Health Qual Life Outcomes; 2021 Jan; 19(1):33. PubMed ID: 33494757
[TBL] [Abstract][Full Text] [Related]
3. Equity, acceptability and feasibility of using polyunsaturated fatty acids in children and adolescents with autism spectrum disorder: a rapid systematic review.
D'Alò GL; De Crescenzo F; Minozzi S; Morgano GP; Mitrova Z; Scattoni ML; Amato L; Davoli M; Schünemann HJ;
Health Qual Life Outcomes; 2020 Apr; 18(1):101. PubMed ID: 32299432
[TBL] [Abstract][Full Text] [Related]
4. Methylphenidate for children and adolescents with autism spectrum disorder.
Sturman N; Deckx L; van Driel ML
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011144. PubMed ID: 29159857
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Memantine for autism spectrum disorder.
Brignell A; Marraffa C; Williams K; May T
Cochrane Database Syst Rev; 2022 Aug; 8(8):CD013845. PubMed ID: 36006807
[TBL] [Abstract][Full Text] [Related]
7. The effectiveness and adverse effects of D-cycloserine compared with placebo on social and communication skills in individuals with autism spectrum disorder.
Aye SZ; Ni H; Sein HH; Mon ST; Zheng Q; Wong YKY
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013457. PubMed ID: 33583058
[TBL] [Abstract][Full Text] [Related]
8. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
Storebø OJ; Storm MRO; Pereira Ribeiro J; Skoog M; Groth C; Callesen HE; Schaug JP; Darling Rasmussen P; Huus CL; Zwi M; Kirubakaran R; Simonsen E; Gluud C
Cochrane Database Syst Rev; 2023 Mar; 3(3):CD009885. PubMed ID: 36971690
[TBL] [Abstract][Full Text] [Related]
9. Dietary interventions for multiple sclerosis-related outcomes.
Parks NE; Jackson-Tarlton CS; Vacchi L; Merdad R; Johnston BC
Cochrane Database Syst Rev; 2020 May; 5(5):CD004192. PubMed ID: 32428983
[TBL] [Abstract][Full Text] [Related]
10. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
Storebø OJ; Ramstad E; Krogh HB; Nilausen TD; Skoog M; Holmskov M; Rosendal S; Groth C; Magnusson FL; Moreira-Maia CR; Gillies D; Buch Rasmussen K; Gauci D; Zwi M; Kirubakaran R; Forsbøl B; Simonsen E; Gluud C
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD009885. PubMed ID: 26599576
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis.
Siafis S; Çıray O; Wu H; Schneider-Thoma J; Bighelli I; Krause M; Rodolico A; Ceraso A; Deste G; Huhn M; Fraguas D; San José Cáceres A; Mavridis D; Charman T; Murphy DG; Parellada M; Arango C; Leucht S
Mol Autism; 2022 Mar; 13(1):10. PubMed ID: 35246237
[TBL] [Abstract][Full Text] [Related]
12. Behavioural and cognitive behavioural therapy for obsessive compulsive disorder (OCD) in individuals with autism spectrum disorder (ASD).
Elliott SJ; Marshall D; Morley K; Uphoff E; Kumar M; Meader N
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013173. PubMed ID: 34693989
[TBL] [Abstract][Full Text] [Related]
13. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Loy JH; Merry SN; Hetrick SE; Stasiak K
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008559. PubMed ID: 28791693
[TBL] [Abstract][Full Text] [Related]
14. Music therapy for people with autism spectrum disorder.
Geretsegger M; Elefant C; Mössler KA; Gold C
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD004381. PubMed ID: 24936966
[TBL] [Abstract][Full Text] [Related]
15. Communication interventions for autism spectrum disorder in minimally verbal children.
Brignell A; Chenausky KV; Song H; Zhu J; Suo C; Morgan AT
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012324. PubMed ID: 30395694
[TBL] [Abstract][Full Text] [Related]
16. Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD).
Reichow B; Hume K; Barton EE; Boyd BA
Cochrane Database Syst Rev; 2018 May; 5(5):CD009260. PubMed ID: 29742275
[TBL] [Abstract][Full Text] [Related]
17. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
Gillies D; Sinn JKh; Lad SS; Leach MJ; Ross MJ
Cochrane Database Syst Rev; 2012 Jul; 2012(7):CD007986. PubMed ID: 22786509
[TBL] [Abstract][Full Text] [Related]
18. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Loy JH; Merry SN; Hetrick SE; Stasiak K
Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
[TBL] [Abstract][Full Text] [Related]
19. Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: A systematic review and meta-analysis.
Patra S; Nebhinani N; Viswanathan A; Kirubakaran R
Autism Res; 2019 Apr; 12(4):542-552. PubMed ID: 30653855
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
